Predicted probability of high adherence to maintenance treatments per posthoc simplified rheumatoid arthritis model
| Treatment†‡ | Component being rated | Predicted high adherence* probability (% (95% CI)) in patients with RA (n=1943) | |||
| White patients | Non-white patients | ||||
| Low BMQ-General Harm Score (<11) | High BMQ-General Harm Score (≥11) | Low BMQ-General Harm Score (<11) | High BMQ-General Harm Score (≥11) | ||
| Age ≥58 years | |||||
| csDMARD-TNFi combination | TNFi | 96.2 (93.8 to 97.7) | 92.3 (87.9 to 95.2) | 91.0 (85.5 to 94.5) | 82.6 (74.0 to 88.8) |
| TNFi monotherapy | TNFi | 94.5 (89.6 to 97.2) | 89.0 (80.5 to 94.1) | 87.2 (77.0 to 93.3) | 76.3 (61.5 to 86.6) |
| csDMARD-TNFi combination | csDMARD | 90.8 (86.4 to 93.9) | 82.3 (75.1 to 87.7) | 79.6 (70.8 to 86.2) | 64.7 (53.5 to 74.6) |
| csDMARD monotherapy | csDMARD | 84.9 (79.6 to 89.0) | 72.6 (65.0 to 79.0) | 69.0 (59.6 to 77.0) | 51.1 (41.2 to 61.0) |
| Age <58 years | |||||
| csDMARD-TNFi combination | TNFi | 90.7 (86.1 to 93.9) | 82.1 (74.6 to 87.8) | 79.4 (71.0 to 85.8) | 64.5 (53.8 to 74.0) |
| TNFi monotherapy | TNFi | 86.8 (77.6 to 92.6) | 75.7 (62.1 to 85.5) | 72.3 (57.6 to 83.4) | 55.2 (39.0 to 70.3) |
| csDMARD-TNFi combination | csDMARD | 79.0 (71.9 to 84.7) | 64.0 (54.2 to 72.7) | 59.8 (49.7 to 69.2) | 41.3 (31.3 to 51.9) |
| csDMARD monotherapy | csDMARD | 68.2 (60.8 to 74.8) | 50.3 (41.7 to 58.9) | 45.9 (37.3 to 54.9) | 28.6 (21.5 to 36.9) |
*High/full medication adherence: 4-item Morisky Medication Adherence Scale©=4.
†With or without concomitant glucocorticoid.
‡Some combinations are not recommended according to the American College of Rheumatology and European League Against Rheumatism.39 40
BMQ, Beliefs about Medicines Questionnaire; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; csDMARD, conventional synthetic disease-modifying antirheumatic drug.